Welcome to our dedicated page for Bexil news (Ticker: BXLC), a resource for investors and traders seeking the latest updates and insights on Bexil stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bexil's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bexil's position in the market.
Bexil Corporation (OTCID:BXLC) has launched a tender offer to purchase up to 40,000 shares of common stock at $53.25 per share. The offer expires on June 16, 2026 at 5:00 p.m. ET unless extended or earlier terminated.
Offer materials and instructions are available at www.Bexil.com; the board approved the offer but made no recommendation to stockholders.
Summary not available.
Summary not available.
Bexil Corporation (OTC PINK:BXLC) reported a significant net loss of $1.8 million or $2.34 per diluted share for the year ended December 31, 2022, marking a decline from a net income of $6.5 million in 2021. The loss includes unrealized losses of $4.5 million, contrasting with unrealized gains of $4.2 million the previous year. Book value per share decreased to $33.84, a 6% decline from $36.01 in 2021. Investors are encouraged to review the audited annual report for more comprehensive financial insights.
Bexil Corporation (OTC PINK:BXLC) reported a net loss of approximately $0.61 million or $0.81 per share for Q3 2022, compared to a net income of $0.14 million or $0.18 per share in Q3 2021.
For the nine months ended September 30, 2022, the company experienced a net loss of $2.54 million or $3.38 per share, contrasting with a net income of $5.43 million or $6.59 per share for the same period in 2021. Additionally, Bexil recorded unrealized losses of $1.64 million in Q3 2022, significantly higher than the $0.32 million loss for Q3 2021.
Bexil Corporation recently elected John C. Hitchcock and William Winmill as Class III Directors during its Annual Meeting on June 7, 2022. Their terms will last until the 2025 annual meeting. Additionally, the Company amended its bylaws on the same date. Bexil, which operates through a subsidiary, aims to enhance book value per share for its shareholders. The Company emphasizes the significance of book value as a financial performance indicator. For further details, visit Bexil's website.
Bexil Corporation (OTC PINK: BXLC) announced the results of its tender offer, concluding on June 1, 2022, during which it accepted 320 shares at $27.50 per share. Payments for accepted shares will be processed promptly by the depositary. The company may consider further repurchases of shares through various methods, though this announcement is solely informational and does not constitute an offer to purchase shares. Bexil aims to increase its book value per share over time for shareholder benefit.
Bexil Corporation (BXLC) reported its Q1 2022 financial results, showing a decline in net income to approximately $0.14 million or $0.19 per diluted share, down from $2.19 million or $2.65 per diluted share in Q1 2021. The losses from equity security investments amounted to $0.30 million, contrasting with $1.86 million in gains from the previous year. The company's book value per share increased to $36.25 from $29.75. Investors are encouraged to review the full quarterly report for comprehensive insights.
Bexil Corporation (OTC: PINK:BXLC) has announced a tender offer inviting shareholders to sell their shares at $27.50 each, with an aggregate limit of 50,000 shares. The offer will expire on June 1, 2022, at 5:00 p.m. ET. The board of directors has approved this offer, but no recommendations are made regarding whether shareholders should participate. Shareholders need to carefully assess the offering materials and consult their advisors before deciding on their participation.
Bexil Corporation (BXLC) reported a significant year-over-year increase in financial performance for the year ended December 31, 2021. The company's net income attributable to shareholders rose to $6.5 million or $7.99 per diluted share, compared to $1.0 million or $1.13 per diluted share in 2020. The book value per share also experienced a notable increase, reaching $36.01, reflecting a growth of 31% from $27.49 the previous year. Investors are encouraged to refer to the audited annual report for comprehensive insights.